# FDA clears daraxonrasib for previously treated metastatic pancreatic cancer

_Published Wednesday, August 26, 2026 at 5:19 PM EDT · Policy, Products · Latest · Tier 1 — Major_

![FDA Approves Daraxonrasib as First-in-Class Targeted Therapy for Metastatic Pancreatic Cancer | PharmExec — Primary](https://cdn.sanity.io/images/0vv8moc6/pharmexec/497cd6699581ef13dd45c2ae3a9c756d8d9d8201-5000x3750.jpg)

The FDA approved Revolution Medicines' daraxonrasib, marketed as Rasonque, for adults with metastatic pancreatic adenocarcinoma who have received prior systemic therapy or are not candidates for multiagent chemotherapy, PharmExec reported.

The once-daily oral RAS(ON) inhibitor becomes the company's first commercial product. The report said approval was based on the 500-patient RASolute 302 phase 3 trial, which compared daraxonrasib with investigator's-choice chemotherapy after prior treatment. Reported adverse events included rash, diarrhea, stomatitis, nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite, and hemorrhage.

## Sources

- [PharmExec](https://www.pharmexec.com/view/fda-approves-daraxonrasib-targeted-therapy-metastatic-pancreatic-cancer)

---
Canonical: https://techandbusiness.org/newswire/Q62V3F_5CIjmZgoUiPFzl8
Published: 2026-08-26T21:19:16.402Z
Story chronology: 2026-08-26T17:14:29.903Z
Retrieved: 2026-10-11T06:13:23.435Z
Publisher: Tech & Business (techandbusiness.org)